DIFFERENCES IN ONCOGENIC POTENCY BUT NOT TARGET-CELL SPECIFICITY DISTINGUISH THE 2 FORMS OF THE BCR/ABL ONCOGENE

被引:69
作者
KELLIHER, M
KNOTT, A
MCLAUGHLIN, J
WITTE, ON
ROSENBERG, N
机构
[1] TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111
[2] TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,BOSTON,MA 02111
[3] TUFTS UNIV,SCH MED,IMMUNOL GRAD PROGRAM,BOSTON,MA 02111
[4] UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024
[5] UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024
关键词
D O I
10.1128/MCB.11.9.4710
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Two forms of activated BCR/ABL proteins, P210 and P185, that differ in BCR-derived sequences, are associated with Philadelphia chromosome-positive leukemias. One of these diseases is chronic myelogenous leukemia, an indolent disease arising in hematopoietic stem cells that is almost always associated with the P210 form of BCR/ABL. Acute lymphocytic leukemia, a more aggressive malignancy, can be associated with both forms of BCR/ABL. While it is virtually certain that BCR/ABL plays a central role in both of these diseases, the features that determine the association of a particular form with a given disease have not been elucidated. We have used the bone marrow reconstitution leukemogenesis model to test the hypothesis that BCR sequences influence the ability of activated ABL to transform different types of hematopoietic cells. Our studies reveal that both P185 and P210 induce a similar spectrum of hematological diseases, including granulocytic, myelomonocytic, and lymphocytic leukemias. Despite the similarity of the disease patterns, animals given P185-infected marrow developed a more aggressive disease after a shorter latent period than those given P210-infected marrow. These data demonstrate that the structure of the BCR/ABL oncoprotein does not affect the type of disease induced by each form of the oncogene but does control the potency of the oncogenic signal.
引用
收藏
页码:4710 / 4716
页数:7
相关论文
共 55 条
[1]   NUCLEIC-ACID SEQUENCE AND ONCOGENIC PROPERTIES OF THE HZ2 FELINE SARCOMA-VIRUS V-ABL INSERT [J].
BERGOLD, PJ ;
BLUMENTHAL, JA ;
DANDREA, E ;
SNYDER, HW ;
LEDERMAN, L ;
SILVERSTONE, A ;
NGUYEN, H ;
BESMER, P .
JOURNAL OF VIROLOGY, 1987, 61 (04) :1193-1202
[2]  
CHAMPLIN RE, 1985, BLOOD, V65, P1039
[3]   A NOVEL ABL PROTEIN EXPRESSED IN PHILADELPHIA-CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA [J].
CHAN, LC ;
KARHI, KK ;
RAYTER, SI ;
HEISTERKAMP, N ;
ERIDANI, S ;
POWLES, R ;
LAWLER, SD ;
GROFFEN, J ;
FOULKES, JG ;
GREAVES, MF ;
WIEDEMANN, LM .
NATURE, 1987, 325 (6105) :635-637
[4]  
CHEN SJ, 1988, LEUKEMIA, V2, P261
[5]   LEUKEMIA INITIATED BY HEMATOPOIETIC STEM-CELLS EXPRESSING THE V-ABL ONCOGENE [J].
CHUNG, SW ;
WONG, PMC ;
DURKIN, H ;
WU, YS ;
PETERSEN, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (04) :1585-1589
[6]   UNIQUE FORMS OF THE ABL TYROSINE KINASE DISTINGUISH PH1-POSITIVE CML FROM PH1-POSITIVE ALL [J].
CLARK, SS ;
MCLAUGHLIN, J ;
CRIST, WM ;
CHAMPLIN, R ;
WITTE, ON .
SCIENCE, 1987, 235 (4784) :85-88
[7]  
CLARK SS, 1989, ANNU REV MED, V40, P113
[8]   ABELSON VIRUS TRANSFORMATION OF AN INTERLEUKIN-2-DEPENDENT ANTIGEN-SPECIFIC T-CELL LINE [J].
COOK, WD ;
FAZEKAS DE ST GROTH, B ;
MILLER, JFAP ;
MACDONALD, HR ;
GABATHULER, R .
MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (07) :2631-2635
[9]   MALIGNANT TRANSFORMATION OF A GROWTH FACTOR-DEPENDENT MYELOID CELL-LINE BY ABELSON VIRUS WITHOUT EVIDENCE OF AN AUTOCRINE MECHANISM [J].
COOK, WD ;
METCALF, D ;
NICOLA, NA ;
BURGESS, AW ;
WALKER, F .
CELL, 1985, 41 (03) :677-683
[10]   TRANSFORMATION OF AN INTERLEUKIN-3-DEPENDENT HEMATOPOIETIC-CELL LINE BY THE CHRONIC MYELOGENOUS LEUKEMIA-SPECIFIC P210BER/ABL PROTEIN [J].
DALEY, GQ ;
BALTIMORE, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (23) :9312-9316